Deal Details
GTP Is Acquired by Olon
Summary
Bioways Holding SAS (“GTP Bioways” or "GTP"), a portfolio company of Mérieux Equity Partners (“MxEP”), has been acquired by Olon Group (“Olon”). Terms of the transaction were not disclosed. The transaction is subject to various regulatory approvals and customary closing conditions.
Baird served as the exclusive financial advisor to GTP and MxEP on this transaction.
About
GTP is an expert and fast-growing contract development and manufacturing organization (CDMO) specialised in process development and manufacturing of antibodies, proteins, bioconjugates and nanodrugs. GTP has strong expertise in working with a diversified range of expression systems (mammalian, bacterial, yeast, insect cells) and molecules (mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). With additional facilities in Labège, Saint-Julien-en-Genevois and Veyre-Monton, GTP is headquartered in Toulouse, France.MxEP is an AMF-accredited management company dedicated to equity investments in Healthcare. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages c.€1.5bn AUM. MxEP is headquartered in Lyon, France.
Olon, located in Italy, is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes. Olon has a global network of 11 manufacturing sites and 7 R&D centers across the globe. Olon is headquartered in Rodano, Italy.
CONTACT US TO LEARN MORE
- Date
- July 2024
- Company
- Bioways Holding SAS and Mérieux Equity Partners
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- Europe
- Acquiror Geography
- Europe
Share
